GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Researchers have determined in a new study that the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...

A recent phase III randomized trial found an investigational oral small-molecule GLP-1 receptor agonist significantly ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

Employers are grappling with the ripple effect of an increasingly popular weight loss treatment. Pharmacy benefit leaders at Holmes Murphy share what to consider when evaluating GLP-1s for your ...